Tyra Biosciences Inc
Research Tyra Biosciences Inc (TYRA) on Bullrun: market cap USD 1.59B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTYRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.59B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 45.56M
- Free cash flow-USD 31.14M
Valuation Snapshot
latest market cap is USD 1.59B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 119.95M | -USD 95.28M | n/a | -2.01 | USD 77.39M | USD 5.81M | USD 259.18M |
| FY2024 | USD 0 | -USD 86.48M | -USD 70.44M | n/a | -1.51 | USD 91.97M | USD 6.22M | USD 343.15M |
| FY2023 | n/a | -USD 69.13M | -USD 50.91M | n/a | -1.62 | USD 58.01M | USD 6.50M | USD 204.26M |
| FY2022 | n/a | -USD 55.33M | -USD 50.84M | n/a | -1.32 | USD 251.21M | USD 2.67M | USD 257.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.59B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.41B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 705.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 596.36M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 320.70M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 583.08M | n/a | n/a | n/a |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tyra Biosciences Inc's market cap?
Tyra Biosciences Inc's market capitalization is USD 1.59B.
What does Tyra Biosciences Inc do?
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.